glycated insulin

02/01/2006 - "There is mounting evidence that elevated circulating concentrations of glycated insulin play a role in insulin resistance in type 2 diabetes. "
01/01/2021 - "Overall, this study demonstrates the role of glycated insulin in exacerbating insulin resistance by impairing insulin signaling as well as stimulating AGE-RAGE signaling."
01/01/2021 - "Molecular investigation of glycated insulin-induced insulin resistance via insulin signaling and AGE-RAGE axis."
01/01/2021 - "Reduced biological activity of glycated insulin could be either due to reduced affinity for the insulin receptor and impaired insulin signaling, or it can act as a ligand for the receptor for advanced glycation end products (RAGE) and activates oxidative stress and pro-inflammatory pathways leading to insulin resistance. "

05/01/2003 - "These data demonstrate that glycated insulin circulates at relatively high concentrations in type 2 diabetes with a diurnal pattern of basal and meal-stimulated release. "
05/01/2003 - "We measured 24-hour profiles of plasma glycated insulin, using a novel radioimmunoassay (RIA), to evaluate the effects of meal stimulation and intermittent fasting on circulating concentrations of plasma glycated insulin in type 2 diabetes. "
04/01/2003 - "Demonstration of increased concentrations of circulating glycated insulin in human Type 2 diabetes using a novel and specific radioimmunoassay."
02/01/2006 - "There is mounting evidence that elevated circulating concentrations of glycated insulin play a role in insulin resistance in type 2 diabetes. "
05/01/2003 - "Increasing evidence supports a role for glycated insulin in the insulin-resistant state of type 2 diabetes. "

09/01/2000 - "These data indicate that the impaired biological activity of glycated insulin may contribute to glucose intolerance of diabetes."
12/01/1997 - "These data indicate that glycated insulin exhibits impaired biological activity which may contribute to glucose intolerance in diabetes. "

12/01/1997 - "Glucose-lowering activities of glycated and control (non-glycated) insulin preparations were assessed in mice by intraperitoneal injection in a 39% (w/v) glucose solution (2 g/kg body weight) at doses of 0.05 and 0.25 units/kg body weight. "